Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis

Kinetic stabilization of the native state

H. Michael Petrassi, Steven Johnson, Hans E. Purkey, Kyle P. Chiang, Traci Walkup, Xin Jiang, Evan T. Powers, Jeffery W. Kelly

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Transthyretin (TTR) amyloidogenesis requires rate-limiting tetramer dissociation and partial monomer denaturation to produce a misassembly competent species. This process has been followed by turbidity to identify transthyretin amyloidogenesis inhibitors including dibenzofuran-4,6-dicarboxylic acid (1). An X-ray cocrystal structure of TTR-12 reveals that it only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amyloidogenesis. Herein, structure-based design was employed to append aryl substituents at C1 of the dibenzofuran ring to complement the unused inner portion of the thyroxine binding pockets. Twenty-eight amyloidogenesis inhibitors of increased potency and dramatically increased plasma TTR binding selectivity resulted. These function by imposing kinetic stabilization on the native tetrameric structure of TTR, creating a barrier that is insurmountable under physiological conditions. Since kinetic stabilization of the TTR native state by interallelic trans suppression is known to ameliorate disease, there is reason to be optimistic that the dibenzofuran-based inhibitors will do the same. Preventing the onset of amyloidogenesis is the most conservative strategy to intervene clinically, as it remains unclear which of the TTR misassembly intermediates results in toxicity. The exceptional binding selectivity enables these inhibitors to occupy the thyroxine binding site(s) in a complex biological fluid such as blood plasma, required for inhibition of amyloidogenesis in humans. It is now established that the dibenzofuran-based amyloidogenesis inhibitors have high selectivity, affinity, and efficacy and are thus excellent candidates for further pharmacologic evaluation.

Original languageEnglish (US)
Pages (from-to)6662-6671
Number of pages10
JournalJournal of the American Chemical Society
Volume127
Issue number18
DOIs
StatePublished - May 11 2005
Externally publishedYes

Fingerprint

Prealbumin
Stabilization
Plasmas
Denaturation
Kinetics
Turbidity
Binding sites
Toxicity
Blood
Monomers
Thyroxine
X rays
Fluids
Acids
dibenzofuran
Binding Sites
X-Rays

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis : Kinetic stabilization of the native state. / Petrassi, H. Michael; Johnson, Steven; Purkey, Hans E.; Chiang, Kyle P.; Walkup, Traci; Jiang, Xin; Powers, Evan T.; Kelly, Jeffery W.

In: Journal of the American Chemical Society, Vol. 127, No. 18, 11.05.2005, p. 6662-6671.

Research output: Contribution to journalArticle

Petrassi, H. Michael ; Johnson, Steven ; Purkey, Hans E. ; Chiang, Kyle P. ; Walkup, Traci ; Jiang, Xin ; Powers, Evan T. ; Kelly, Jeffery W. / Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis : Kinetic stabilization of the native state. In: Journal of the American Chemical Society. 2005 ; Vol. 127, No. 18. pp. 6662-6671.
@article{3821c261477846c193862c6d5468c690,
title = "Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: Kinetic stabilization of the native state",
abstract = "Transthyretin (TTR) amyloidogenesis requires rate-limiting tetramer dissociation and partial monomer denaturation to produce a misassembly competent species. This process has been followed by turbidity to identify transthyretin amyloidogenesis inhibitors including dibenzofuran-4,6-dicarboxylic acid (1). An X-ray cocrystal structure of TTR-12 reveals that it only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amyloidogenesis. Herein, structure-based design was employed to append aryl substituents at C1 of the dibenzofuran ring to complement the unused inner portion of the thyroxine binding pockets. Twenty-eight amyloidogenesis inhibitors of increased potency and dramatically increased plasma TTR binding selectivity resulted. These function by imposing kinetic stabilization on the native tetrameric structure of TTR, creating a barrier that is insurmountable under physiological conditions. Since kinetic stabilization of the TTR native state by interallelic trans suppression is known to ameliorate disease, there is reason to be optimistic that the dibenzofuran-based inhibitors will do the same. Preventing the onset of amyloidogenesis is the most conservative strategy to intervene clinically, as it remains unclear which of the TTR misassembly intermediates results in toxicity. The exceptional binding selectivity enables these inhibitors to occupy the thyroxine binding site(s) in a complex biological fluid such as blood plasma, required for inhibition of amyloidogenesis in humans. It is now established that the dibenzofuran-based amyloidogenesis inhibitors have high selectivity, affinity, and efficacy and are thus excellent candidates for further pharmacologic evaluation.",
author = "Petrassi, {H. Michael} and Steven Johnson and Purkey, {Hans E.} and Chiang, {Kyle P.} and Traci Walkup and Xin Jiang and Powers, {Evan T.} and Kelly, {Jeffery W.}",
year = "2005",
month = "5",
day = "11",
doi = "10.1021/ja044351f",
language = "English (US)",
volume = "127",
pages = "6662--6671",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis

T2 - Kinetic stabilization of the native state

AU - Petrassi, H. Michael

AU - Johnson, Steven

AU - Purkey, Hans E.

AU - Chiang, Kyle P.

AU - Walkup, Traci

AU - Jiang, Xin

AU - Powers, Evan T.

AU - Kelly, Jeffery W.

PY - 2005/5/11

Y1 - 2005/5/11

N2 - Transthyretin (TTR) amyloidogenesis requires rate-limiting tetramer dissociation and partial monomer denaturation to produce a misassembly competent species. This process has been followed by turbidity to identify transthyretin amyloidogenesis inhibitors including dibenzofuran-4,6-dicarboxylic acid (1). An X-ray cocrystal structure of TTR-12 reveals that it only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amyloidogenesis. Herein, structure-based design was employed to append aryl substituents at C1 of the dibenzofuran ring to complement the unused inner portion of the thyroxine binding pockets. Twenty-eight amyloidogenesis inhibitors of increased potency and dramatically increased plasma TTR binding selectivity resulted. These function by imposing kinetic stabilization on the native tetrameric structure of TTR, creating a barrier that is insurmountable under physiological conditions. Since kinetic stabilization of the TTR native state by interallelic trans suppression is known to ameliorate disease, there is reason to be optimistic that the dibenzofuran-based inhibitors will do the same. Preventing the onset of amyloidogenesis is the most conservative strategy to intervene clinically, as it remains unclear which of the TTR misassembly intermediates results in toxicity. The exceptional binding selectivity enables these inhibitors to occupy the thyroxine binding site(s) in a complex biological fluid such as blood plasma, required for inhibition of amyloidogenesis in humans. It is now established that the dibenzofuran-based amyloidogenesis inhibitors have high selectivity, affinity, and efficacy and are thus excellent candidates for further pharmacologic evaluation.

AB - Transthyretin (TTR) amyloidogenesis requires rate-limiting tetramer dissociation and partial monomer denaturation to produce a misassembly competent species. This process has been followed by turbidity to identify transthyretin amyloidogenesis inhibitors including dibenzofuran-4,6-dicarboxylic acid (1). An X-ray cocrystal structure of TTR-12 reveals that it only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amyloidogenesis. Herein, structure-based design was employed to append aryl substituents at C1 of the dibenzofuran ring to complement the unused inner portion of the thyroxine binding pockets. Twenty-eight amyloidogenesis inhibitors of increased potency and dramatically increased plasma TTR binding selectivity resulted. These function by imposing kinetic stabilization on the native tetrameric structure of TTR, creating a barrier that is insurmountable under physiological conditions. Since kinetic stabilization of the TTR native state by interallelic trans suppression is known to ameliorate disease, there is reason to be optimistic that the dibenzofuran-based inhibitors will do the same. Preventing the onset of amyloidogenesis is the most conservative strategy to intervene clinically, as it remains unclear which of the TTR misassembly intermediates results in toxicity. The exceptional binding selectivity enables these inhibitors to occupy the thyroxine binding site(s) in a complex biological fluid such as blood plasma, required for inhibition of amyloidogenesis in humans. It is now established that the dibenzofuran-based amyloidogenesis inhibitors have high selectivity, affinity, and efficacy and are thus excellent candidates for further pharmacologic evaluation.

UR - http://www.scopus.com/inward/record.url?scp=18644384035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644384035&partnerID=8YFLogxK

U2 - 10.1021/ja044351f

DO - 10.1021/ja044351f

M3 - Article

VL - 127

SP - 6662

EP - 6671

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 18

ER -